

To All Concerned Parties,

Company: Asahi Intecc Co., Ltd.
Representative: Masahiko Miyata, President & CEO
(Securities code: 7747, Prime of Tokyo Stock Exchange and Premier of
Nagoya Stock Exchange)
Contact:
Mizuho Ito, Member of Board & CFO, General Manager of Administration
(TEL. +81-561-48-5551)

Notice Regarding a Basic Agreement for the Exclusive Sales of Penumbra's Peripheral Vascular Thrombus Aspiration Device in the Japanese Market

Asahi Intecc Group announces that it has signed a basic agreement with Penumbra, Inc. (hereinafter referred to as "Penumbra"), for the exclusive sales of peripheral vascular thrombus aspiration device "Indigo™ and Lightning™ system" in the Japanese market by its consolidated subsidiary, Asahi Intecc J-sales, Inc.

1. Background

In Japan, surgical treatment and thrombolytic drug therapy are selected for the treatment of acute diseases such as acute limb ischemia (ALI), deep vein thrombosis (DVT) and pulmonary embolism (PE), which occur when a thrombus occludes a peripheral artery. Currently, urokinase products used in thrombolytic drug therapy is in short supply, which may eliminate treatment options for patients who are unable to undergo surgical procedures. Therefore, the early introduction of a peripheral vascular thrombus aspiration system is needed.

Penumbra, a U.S. company, designs, develops, manufactures, and markets medical devices which is useful for removing thrombi from peripheral vascular. Peripheral vascular thrombus aspiration device "Indigo™ and Lightning™ system" are thrombus aspiration catheter systems using a mechanical pump, however these products have not been approved under the Japanese Pharmaceutical and Medical Device Act at this point.

The Group is actively developing its business in the peripheral vascular system area in line with its medium-to long-term strategy of "Expand affected / treatment areas." Through the alliance with Penumbra, the Group will strive to meet society's medical needs, promote minimally invasive treatment, and improve the quality of life (QOL) of doctors and patients.

2. Future deployment

Based on this agreement, the two companies will proceed with discussions and preparatory activities for the introduction of the system, aiming to reach a final agreement by mid-February 2023.

3. Overview of Penumbra

Company name:	Penumbra Inc.
Name and title of representative:	Adam Elsesser, President, Chairman and Chief Executive Officer
Location:	California, the United States of America
Establishment:	2004
Listed market:	New York Stock Exchange
Revenue:	747 million (FYE December, 2021)
Business area:	Design, develop, manufacture and market for vascular medical devices
URL:	https://www.penumbrainc.com/

4. Future outlook

There will be no revision of the Company's consolidated earnings forecast for the full fiscal year announced on August 12, 2022.